MedPath

URSAPHARM Arzneimittel GmbH

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:1
Phase 4:1

Drug Approvals

5

NMPA:2
PHILIPPINES:2
SFDA:1

Drug Approvals

Sodium Hyaluronate Eye Drops

Product Name
玻璃酸钠滴眼液
Approval Number
国药准字HJ20240162
Approval Date
Dec 6, 2024
NMPA

Azelastine Hydrochloride Eye Drops

Product Name
盐酸氮䓬斯汀滴眼液
Approval Number
国药准字HJ20230059
Approval Date
May 29, 2023
NMPA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 4
1 (50.0%)

Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis

Phase 4
Completed
Conditions
Blepharitis
Signs and Symptoms
Interventions
Drug: Placebo Comparator
First Posted Date
2011-05-20
Last Posted Date
2011-05-20
Lead Sponsor
Ursapharm Arzneimittel GmbH
Target Recruit Count
197
Registration Number
NCT01357538
Locations
🇺🇦

Kharkov District Clinical Hospital, Kharkov, Ukraine

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.